HCW Biologics (HCWB) said Tuesday its board has approved a 1-for-40 reverse split of its common stock, effective April 11, to regain compliance with Nasdaq's $1 minimum bid price requirement.
The move will reduce the company's total number of issued and outstanding common shares to about 1.1 million from 44.9 million.
Shares will start trading on a split-adjusted basis also on April 11.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.